ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.
Four years after British Columbia announced its Biosimilars Initiative and seven provinces and two territories followed suit, Arthritis Research Canada – the country's largest clinical arthritis research organization – is sharing its findings about how this policy change is affecting people living with arthritis.